Blood test for EGFR mutations in advanced lung cancer
Part of Cancer clinical trials.
This study is testing a new blood test that can find EGFR gene changes (mutations) in people with advanced lung cancer. The test may help doctors choose better treatments by detecting these mutations more easily and accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung cancer that has spread (advanced stage).
- You are willing to follow the study procedures and give written permission to join.
- You do not have another active cancer right now.
- You do not have severe lung conditions like asthma, COPD, or a history of heavy dust exposure.
- Your medical records and information are available for review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special light-based blood test to tell the difference between benign (non-cancerous) and malignant (cancerous) growths in the lungs. It aims to help doctors diagnose lung cancer more accurately and earlier.
This study uses leftover tissue or fluid from your lung cancer to test how it responds to different drugs in the lab. The goal is to understand which treatments might work best for tumors with EGFR mutations, which could help guide future treatment decisions.
This trial uses a simple blood test during chemotherapy before surgery to see how well the treatment is working. It is for people with operable lung cancer that has an EGFR mutation, and may help guide their treatment.
This trial tests a new blood test that can detect a specific genetic change (EGFR T790M) in advanced lung cancer. It aims to see if the test works well for guiding treatment decisions.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
Hear when a new Lung Cancer in Normal and Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.